FDA Eyeing Other PD-1/L1 Drugs With Clinical Hold On Keytruda Myeloma Trials

 
• By Michael Cipriano

Merck previously disclosed the clinical hold on the three trials at the beginning of July; FDA says its announcement is meant to inform patients and healthcare providers about the danger of the safety signal.

Yellow road sign with a blue sky and white clouds: clinical trial
US FDA has detailed the data that led to a clinical hold on Keytruda multiple myeloma trials

More from Drug Safety

More from Pink Sheet